Table 2.
Summary of tumor response with sunitinib plus trastuzumab
| |
n (%) |
||||||
|---|---|---|---|---|---|---|---|
| Response parameter |
All patients |
Treatment-naïve or prior adjuvant treatment* only |
Prior first-line treatment* |
Visceral disease
†
|
Non-visceral disease |
Estrogen-receptor positive |
Estrogen-receptor negative |
| (n = 57) | (n = 34) | (n = 23) | (n = 41) | (n = 16) | (n = 30) | (n = 27) | |
| Complete response |
2 (4) |
2 (6) |
0 |
1 (2) |
1 (6) |
2 (7) |
0 |
| Partial response |
19 (33) |
13 (38) |
6 (26) |
17 (41) |
2 (13) |
8 (27) |
11 (41) |
| Stable disease |
21 (37) |
10 (29) |
11 (48) |
15 (37) |
6 (38) |
13 (43) |
8 (30) |
| 24 weeks |
11 (19) |
5 (15) |
6 (26) |
6 (15) |
5 (31) |
6 (20) |
5 (19) |
| Objective response |
21 (37) |
15 (44) |
6 (26) |
18 (44) |
3 (19) |
10 (33) |
11 (41) |
| 95% exact CI |
24–51 |
27–62 |
10–48 |
28–60 |
4–46 |
17–53 |
22–61 |
| Clinical benefit‡ |
32 (56) |
20 (59) |
12 (52) |
24 (59) |
8 (50) |
16 (53) |
16 (59) |
| 95% exact CI | 42–69 | 41–75 | 31–73 | 42–74 | 25–75 | 34–72 | 39–78 |
*Chemotherapy, trastuzumab, and/or lapatinib.
†Liver and/or lung.
‡Objective response or stable disease ≥ 24 weeks.